Transcatheter Arterial Infusion of Autologous CD133⁺ Cells for Diabetic Peripheral Artery Disease

Figure 2

ABI and TcPO₂ difference before and after treatment. TcPO₂ and ABI were improved significantly in CD133⁺ group than control at 18 months and did not improve at 1 month, indicating a delayed and persistent perfusion-improving benefit of CD133⁺ progenitor cell treatment. “∘” represents mild outliers in boxplot, and the small numbers beside it represent the case numbers.